Laura Stoppel
Partner·RA Capital Management
Laura Stoppel is a Partner on RA Capital's Investment Team, where she works on both public and private investments. She serves as a board director for Artiva Biotherapeutics, Nimbus Therapeutics, and Acumen Pharmaceuticals, and CellCentric lists her as an investor director and board member. She previously covered hematologic malignancies, cell therapies, retinal diseases, and orphan neurodevelopmental disorders, and her graduate research investigated synaptic translation in syndromic autism.
See the rest of Laura Stoppel's profile.
Deal history, investment focus, outreach angles and the rest of the background. One email, no password — we send a link and you land right back here.